Lymph Node Biopsy - Lymphoma Workup Essentials

Key Points

• Adequate tissue and architecture are central to new lymphoma diagnosis.
• Excisional biopsy is preferred when feasible; multiple cores are an acceptable alternative in many deep sites.
• FNA alone is often insufficient for definitive classification.
• Tell pathology in advance so fresh tissue can be triaged for flow cytometry.
• Hodgkin lymphoma may have negative or nondiagnostic flow cytometry despite disease.
• Immunohistochemistry, FISH, and molecular studies should be selected from the morphologic differential.
• Avoid prebiopsy corticosteroids when clinically safe because they can obscure diagnosis.
• Discordant clinical and pathology findings warrant repeat or more definitive biopsy.

Algorithm

1. Select the safest accessible node that is likely to contain viable disease.
2. Notify pathology that lymphoma is suspected before the procedure.
3. Obtain excisional tissue when feasible or multiple adequate core samples.
4. Send fresh tissue for flow cytometry and fixed tissue for histology and immunohistochemistry.
5. Use morphology to guide immunophenotypic, FISH, and molecular studies.
6. Correlate the final subtype with PET/CT or other staging imaging and clinical findings.
7. Obtain baseline labs and infection screening required before therapy.
8. If results are nondiagnostic or discordant, obtain additional tissue rather than forcing a classification.

Clinical Synopsis & Reasoning

Lymphoma diagnosis differs from many solid tumors because classification often depends on lymph-node architecture, cell morphology, immunophenotype, genetic abnormalities, and clinical distribution. A fine-needle aspirate can identify an abnormal lymphoid population but is often insufficient to classify a new lymphoma. CAP and ASCP guidance supports obtaining adequate tissue, preferably excisional biopsy when feasible, or a generous image-guided core biopsy when excision is impractical or unsafe.

Before biopsy, identify the most informative and accessible site. Avoid necrotic nodes when a viable alternative exists. PET/CT can help select a metabolically active site in patients with disseminated disease, but imaging does not replace histology. A superficial node can often be excised, preserving architecture and providing enough tissue for broad testing. Deep abdominal, mediastinal, or medically high-risk sites may be sampled with multiple large-gauge cores under image guidance.

Communicate suspicion for lymphoma before the specimen is placed in formalin. A fresh portion should often be sent for flow cytometry, with the remainder fixed for histology and immunohistochemistry. Hodgkin lymphoma can be missed by flow because malignant cells are sparse, making architecture and immunohistochemistry particularly important. T-cell lymphomas may require T-cell receptor gene-rearrangement studies, while selected B-cell neoplasms require FISH or molecular testing.

Treatment Strategy & Disposition

The pathology workup begins with morphology and a targeted immunohistochemical panel rather than a universal battery. B-cell markers, T-cell markers, proliferation index, germinal-center markers, cyclin D1, ALK, EBV studies, and others are chosen from the differential. FISH can detect rearrangements such as MYC, BCL2, BCL6, CCND1, or ALK when the phenotype and morphology warrant testing. Molecular sequencing is increasingly useful but should complement, not replace, morphology and immunophenotype.

Peripheral blood, bone marrow, and cerebrospinal fluid are not automatically required for every lymphoma. Their use depends on subtype, stage, symptoms, and treatment plan. Once a diagnosis is established, staging commonly uses PET/CT for FDG-avid lymphomas and CT for selected indolent subtypes. Baseline CBC, CMP, LDH, uric acid, hepatitis B, hepatitis C, and HIV testing often affect prognosis or treatment safety.

If the initial biopsy is nondiagnostic but clinical suspicion remains high, obtain more tissue rather than accepting 'reactive' pathology that does not fit the imaging and course. Corticosteroids can cause rapid lymphoma cytolysis and should be avoided before diagnostic biopsy when clinically safe, especially in mediastinal or CNS disease, because they can make pathology nondiagnostic. Emergency steroid use remains appropriate when airway, spinal cord, or other organ function is threatened.

Epidemiology / Risk Factors

• Non-Hodgkin and Hodgkin lymphomas comprise many biologically distinct diseases.
• Incidence rises with age for many subtypes, while Hodgkin lymphoma has a different age distribution.
• Immunodeficiency, EBV and other infections, autoimmune disease, and certain therapies alter lymphoma risk.
• Precise subtype determines prognosis and treatment far more than the generic word 'lymphoma.'

Investigations

Tests Often Needed

Pharmacology

Prognosis / Complications

• Many lymphomas are highly treatable and several are curable.
• Prognosis depends on subtype, molecular features, stage, performance status, LDH, and treatment response.
• Delayed or incorrect classification can expose patients to ineffective therapy.
• Modern response assessment increasingly uses PET/CT in FDG-avid disease.

Patient Education / Counseling

• Explain why a larger biopsy may be recommended instead of a needle aspirate alone.
• Tell the patient that additional molecular or flow results can take longer than the initial microscopic diagnosis.
• Review risks of bleeding, infection, and anesthesia based on biopsy site.
• Patients should report rapidly worsening dyspnea, stridor, neurologic deficits, or severe pain because some lymphoma complications require treatment before the full workup is complete.
• Clarify that staging studies are performed after the subtype is known because different lymphomas behave differently.

Notes

The best lymphoma biopsy is not necessarily the largest node. It is the safest site that is representative, viable, and can provide the tissue types required for classification.

A practical communication failure occurs when the proceduralist thinks 'pathology will decide what tests to run' after all tissue has already been fixed. Lymphoma workup often requires decisions at the moment of collection.

References

1. CAP/ASCP: Laboratory Workup of Lymphoma in Adults — Link
2. WHO Classification of Haematolymphoid Tumours — Link